Jounce Therapeutics to Present Two Posters from the JTX-2011 Program at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

On November 2, 2018 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that data derived from its JTX-2011 program will be presented in two poster sessions at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 33rd Annual Meeting, being held November 9-11, 2018 in Washington, D.C (Press release, Jounce Therapeutics, NOV 2, 2018, View Source;p=RssLanding&cat=news&id=2375150 [SID1234530608]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Details:

Poster Title: Emergence of an ICOS hi CD4 T cell subset correlates with tumor reductions in subjects treated with the ICOS agonist antibody JTX-2011
Author: Christopher Harvey Ph.D., Jounce Therapeutics, Inc.
Session: Biomarkers and Immune Monitoring
Poster Session Number: 52
Location: Hall E
Date and Time: Saturday, November 10, 2018; 12:20pm–1:50pm ET and 7:00pm–8:30pm ET

Poster Title: Inducible T cell Co-stimulator (ICOS) is upregulated on lymphocytes following radiation of tumors and ICOS agonism in combination with radiation results in enhanced tumor control
Author: Michael J. Gough Ph.D., Earle A. Chile’s Research Institute, Providence Portland Medical Center, Portland Oregon
Session: Immune Effects of Chemotherapy, Radiation and Targeted Therapies
Poster Session Number: 455
Location: Hall E
Date and Time: Friday, November 9, 2018; 12:45pm–2:15pm ET and 6:30pm–8pm ET

About JTX-2011
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.